CYDY · CytoDyn Inc.
$0.25
+0.01 (+3.67%)
At close · Aug 26
Going-concern doubt
— flagged Apr 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, including the various matters discussed in Note 10, *Commitments and Contingencies*, raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Apr 8, 2026
Market Cap
$327.85M
Shares
1.37B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.25
Open$0.25
Day$0.23–0.26
52W close$0.19–0.37
Avg vol 30d1.5M
Short int36.4M · 2.7% float · 17.1d
Short vol49%
DataJan 2020–Aug 2026
Filing10-Q · Apr 8
Up next
FQ1-27 quarter ends
~Aug 31, 2026
Est
filed Apr 8, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−8%
below
Price vs 50-day avg
+14%
above
RSI (14)
76
overbought
MACD trend
Positive
52-week position
34%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+31%
trailing
6-month return
+4%
trailing
YTD return
−11%
this year
Relative strength
−9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-33% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.66% of float · ▼ -0.1% MoM · 17.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 3-yr low, contrarian setup
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+100%
Y/Y
Free cash flow
$-8.9M
Balance sheet
$9.6M
net cash
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−8%
Bearish
Price vs 50-day avg
+14%
Bullish
RSI (14)
76
Bearish
MACD trend
Positive
Bullish
52-week position
34%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-33% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.66% of float · ▼ -0.1% MoM · 17.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 34%
Range high $0
vs 200-day avg -8%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CYDY
this stock
CytoDyn Inc.
|
$327.85M | -11.1% | -100.0% | — | 2.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
6
- % held
- 0.0%
- Net QoQ
- -170.5K sh
- Top holder
- Diversified Trust Co
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CYDY | +24.4% | +31.0% | +3.7% | +31.0% | -11.1% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +24.8% | +25.9% | -8.8% | +28.4% | -23.5% |